Abstract library

68 results for "gep-nen".
#398 Ileal GEP-NEN in Mother and Son – Option for Familial Disease
Introduction: Familial cases of ileal GEP-NEN have been described on some few occasions in the literature. Speculations of familial disease with or without a relationship to MEN-1 or other inherited endocrine neoplasias have been made
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Joakim Hennings
#1598 The Exploration of the Clinical Value of Plasma CgA in Nonfunctional Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: Controversies still remain on the clinical value of CgA.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Yang Lv
Authors: Lv Y, Han X, Mao W, Zhou J, ...
#1788 Prospective Observational Study 1 on the Prognosis of Patients with Unresectable Advanced Gastrointestinal and Pancreatic Neuroendocrine Tumors (PROP-UP 1 Study) in Japan
Introduction: No previous observational studies on the prognosis of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) [pancreatic neuroendocrine neoplasms (PNENs) and gastrointestinal neuroendocrine neoplasms (GI-NENs)] exist in Japan.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Kazuhiro Toriyama
Keywords: prop-up, japan, gep-nen
#1121 Epidemiology and Classification of Gastroenteropancreatic Neuroendocrine Neoplasms Using the WHO 2010 Criteria: A Cohort Study in a Defined Norwegian Population.
Introduction: Incidence figures of gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) still remain uncertain.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Oddvar Sandvik
Keywords: GEP-NEN, epidemiology, WHO
#1397 The Relation Between GEP-NEN Prognosis Re-Stratification and Ki-67 Variability: From a Single Institution Study
Introduction: Ki-67 has been identified as a prognostic factor for GEP NEN.The variability of Ki-67 during the disease course has been reported,but there's few about its effects on prognosis.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Zhang Qin
Authors: Rong L, Qin Z, ...
#1404 The Proteasome Inhibitor Bortezomib Is a Highly Effective Treatment Option for Gastroenteropancreatic Neuroendocrine Neoplasms and Sensitizes to DNA Damaging Therapy In Vitro
Introduction: Gastroenteropancreatic neuroendocrine neoplasms are fairly rare tumors with very heterogeneous behavior and molecular characteristics. Their generally slow proliferation render them virtually resistant to many DNA damaging therapeutic approaches. Bortezomib has been shown to be effective in GEP-NENs in vitro but has been withdrawn from clinical assessment due to a small phase II study on bortezomib monotherapy in 2004.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Franziska Briest
#1507 The CDK4/6 Inhibitor Palbociclib Induces Anti-proliferative Mechanisms in Gastroenteropancreatic Neuroendocrine Neoplasms In Vitro
Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors with heterogeneous molecular backgrounds and mostly unknown druggable driver mutations. Especially for the midgut NENs effective treatment options are limited. The retinoblastoma pathway is often inactive due to CDK4/6 overexpression in pancreatic NENs. Palbociclib is a FDA approved (ER-positive and HER2-negative breast cancer) cyclin-dependent kinases 4 and 6 inhibitor and might impair cell cycle progression and proliferation.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Franziska Briest
#1334 Early Evaluation of Sunitinib in Treatment of Advanced Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) by CT Imaging: RECIST or Choi Criteria?
Introduction: There is no study to assess RECIST and Choi criteria in evaluating response of advanced GEP-NENs treated with sunitinb.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Yanji Luo
Authors: Luo Y, Chen J, Li Z P, Feng S T, ...
#1589 Clinicopathologic Characteristics and Survival of Patients with Gastro-Enteropancreatic Neuroendocrine Neoplasm (GEP-NEN) in a Multi-Ethnic Asian Institution
Introduction: Recent findings suggest epidemiologic differences in gastro-enteropancreatic neuroendocrine neoplasm (GEP-NEN) between population studies.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD David Tai
Authors: Tai W D, Tan S H, Tan D M, Loke K S, ...
Keywords: carcinoid
#1599 The Value of Plasma CgA Combined with NSE Performed As the Real-Time Monitor of Clinical Characteristics in Gastroenteropancreatic Neuroendocrine Neoplasms after the Resection of Primary Lesions
Introduction: Controversies still remain on the clinical value of CgA and NSE.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Yang Lv
Authors: Lv Y, Han X, Mao W, Zhou J, ...
Keywords: cga, nse, nf-gep-nens
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.